ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
Rapid reversal of cytokine storm in septic patients Enhanced resolution of biomarkers for inflammation including leukocytosis compared to standard of care No treatment-related serious
Loreto Gesualdo Arthur Rouill Cyrille Tupin Louis Victor Delouvrier Connie Peyrottes University Of Bari Aldo Moro
Source: finanznachrichten.de